Infantile myofibromatosis is one of the most prevalent soft tissue tumors of infancy and childhood. Multifocal nodules with visceral lesions are associated with a poor prognosis. A few familial cases have been linked to mutations in various genes including PDGFRB. In this study, we sequenced PDGFRB, which encodes a receptor tyrosine kinase, in 16 cases of myofibromatosis or solitary myofibroma. Mutations in the coding sequence of PDGFRB were identified in 6 out of 8 patients with the sporadic multicentric form of the disease and in 1 out of 8 patients with isolated myofibroma. Two patients had the same mutation in multiple separated lesions. By contrast, a third patient had three different PDGFRB mutations in the three nodules analyzed. Mutations were located in the transmembrane, juxtamembrane and kinase domains of the receptor. We showed that these mutations activated receptor signaling in the absence of ligand and transformed fibroblasts. In one case, a weakly-activating germline variant was associated with a stronger somatic mutation, suggesting a two-hit model for familial myofibromatosis. Furthermore, the mutant receptors were sensitive to the tyrosine kinase inhibitor imatinib, except D850V, which was inhibited by dasatinib and ponatinib, suggesting a targeted therapy for severe myofibromatosis. In conclusion, we identified gain-of-function PDGFRB mutations in the majority of multifocal infantile myofibromatosis cases, shedding light on the mechanism of disease development, which is reminiscent of multifocal venous malformations induced by TIE2 mutations. Our results provide a genetic test to facilitate diagnosis, and preclinical data for development of molecular therapies. † The authors wish it to be known that, in their opinion, the second and third authors should be regarded as joint Second Authors.
Introduction
Myofibromatosis is a rare disease characterized by the development of tumor nodules in the skin, bone, muscle and internal organs. It is considered the most common soft tissue neoplasm in infants and young children (1) . Because the majority of affected individuals are below one year of age at diagnosis, it is often referred to as infantile myofibromatosis, but juvenile and adult cases have also been reported. The disease can develop as a solitary myofibroma or multicentric nodules. These tumors are not invasive and often regress spontaneously. However, visceral myofibroblast masses may cause locoregional compression leading to life-threatening complications in 30-70% of cases (1, 2) . Chemotherapy has been suggested for these patients when surgical removal is not possible (3) .
Very little is known about the pathophysiology of myofibromatosis. The vast majority of cases are sporadic, but a few patients with inherited infantile myofibromatosis have been reported. The analysis of these families led to the identification of mutations in candidate genes, including NOTCH3 and PDGFRB, which encodes a receptor tyrosine kinase (RTK) (4, 5) . PDGFRB germline mutations were also described in four patients with premature aging syndrome, Penttinen type (MIM: 601812) and in two cases of Kosaki overgrowth syndrome (MIM: 616592) (6, 7) . We showed that the germline mutations identified in overgrowth and familial myofibromatosis constitutively activate PDGFRB signaling in the absence of its natural ligands (8) . By contrast, dominant loss-of-function variants were associated with idiopathic basal ganglia calcifications (MIM: 615007) (9, 10) .
The PDGFRB receptor, also named PDGFRb, binds to plateletderived growth factor (PDGF)-B and -D, and is highly expressed in fibroblasts, pericytes and other cells of mesenchymal origin (11) (12) (13) . Mice deficient in pdgfb or pdgfrb die from multiple developmental defects including hemorrhages due to a severe lack of pericytes and vascular smooth muscle cells in blood vessels (11) . Ligand binding induces PDGFRB dimerization and a conformation change, which activates the tyrosine kinase domain. The receptor phosphorylation on tyrosine residues creates docking sites for signaling proteins, including phosphatidylinositol-3 kinase (PI3K), STAT transcription factors, phospholipase Cc (PLCc) and GRB2 (12) .
Although PDGF-B is a well-known proto-oncogene, very few PDGFRB gene alterations have been described in cancer (11, 14) . Gene fusions following chromosomal translocations were reported in rare cases of myeloid neoplasms with eosinophilia (14, 15) . This disease can be treated with tyrosine kinase inhibitors such as imatinib, which potently blocks the PDGF receptor kinase activity. The PDGFRB protein is 43% identical to PDGFRA, which is mutated in glioblastomas, inflammatory fibroid polyps and gastrointestinal stromal tumors (GIST), including familial cases (12, 16) . In the present study, using targeted deep sequencing, we show that activating PDGFRB mutations underlie sporadic multifocal myofibromatosis.
Results

PDGFRB mutations in sporadic myofibromatosis
We collected sixteen archived samples of patients diagnosed with myofibromatosis or myofibroma according to the World Health Organization (WHO) classification (17) , from two Belgian academic hospitals: Cliniques Universitaires Saint-Luc and UZ Leuven (Table 1) . Four additional cases with related diseases were included as controls. The slides were reviewed by the study investigators to confirm the diagnosis. The median age at diagnosis was 36 months (birth -44 years old). In addition to six infants, the cohort included seven children and three adults. Sixty-nine percent of cases were males, matching the reported sex bias in this disease (1, 2, 18) . Eight patients had multicentric disease, including one complex case that was previously described in detail (19, 20) . We extracted genomic DNA from frozen or formalin-fixed paraffin-embedded tissue and sequenced PDGFRB using the Ion AmpliSeq Technology (Life technologies). Six samples were analyzed using different panels, which gave highly consistent results (Supplementary Material, Table S1 ). The mean exon coverage depth was >3000 X. We found PDGFRB mutations in seven patients (Tables 1 and 2 ). The presence of mutations was confirmed by allele-specific PCR or Sanger sequencing, as indicated in Table 2 . Six of the seven patients with mutations had multicentric disease (75% of all multicentric cases). The mutated isolated myofibroma case was a child (patient C17); none of the three adults had a mutation. The association between PDGFRB mutation and the multiplicity of lesions was statistically significant (Fisher exact test, p ¼ 0.04). The patients' genotype was not associated with other clinical features.
In two patients (C2 and C5; Table 2 ), DNA was available from healthy tissue, allowing us to rule out germline mutations. The percentages of mutated reads (4-33%) suggested that mutations identified in all patients were somatic, with one exception. In patient C7, c.1681C > T was found in 47% of the reads, which was confirmed by Sanger sequencing and suggested a de novo germline change given the absence of familial history. This mutation (p.R561C) had previously been reported in families with inherited myofibromatosis (4, 5) .
Analysis of patients with multiple PDGFRB mutations
In the same sample from patient C7, a second variant, c.1998C > A (p.N666K) was found in 6% of the reads, indicating a somatic second hit in PDGFRB. In patient C6, we also identified two different PDGFRB mutations in the same nodule (p.W566R and p.N666K, Table 2 ). To assess if these mutations were located in cis (on the same allele of PDGFRB), we extracted RNA from the frozen tumor cells and from the neck tumor of patient C6. Then, we amplified and cloned a fragment of cDNA including the two mutated sites (c.1696T: W566 and c.1998C: N666). Out of 77 sequenced clones from frozen tumor cells, 37 had both mutations, 3 had only c.1998C > A, and 37 were wild-type, demonstrating the existence of a double p.W566R/p.N666K (cis) mutant. The higher percentage of mutations in this analysis compared to the genomic DNA deep sequencing results (Table 2) In three cases, we obtained samples from different lesions of the same patients. In patients C6 and C8, the same mutations were identified in all nodules. Normal tissue DNA was not available to exclude a germline change, but the percentage of mutated reads (4-28%) strongly suggests a post-zygotic somatic or mosaic mutation, which may have appeared in a stem or progenitor cell from which the different nodules originate. By contrast, in patient C5, the three lesions carried three different mutations, c.1998C > A, c.1998C > G and c.1697-1702delGGAAGG, two of which, surprisingly, lead to the same amino-acid substitution (p.N666K; Table 2 ). Analysis of the polymorphisms in each sample confirmed that they belong to the same patient. No mutation was detected in DNA extracted from a nevus and normal skin from the same individual. Together, these data suggest that three independent PDGFRB mutation events led to the development of the three lesions in patient C5.
PDGFRB mutations found in myofibromatosis constitutively activate the receptor
The majority of the mutations that we identified are located in classical hotspots for oncogenic mutations in the PDGFRB receptor family, namely the juxtamembrane and kinase domains. In addition, two patients carry a recurrent insertion in the transmembrane domain of the receptor, p.I538_L539insR (Fig. 1A) . Such a mutation has never been reported in PDGFRB. To analyze the functional impact of these mutations, we first tested whether they transformed mouse fibroblasts in a foci-forming assay. Figure 1B shows that all identified somatic mutations strongly induced foci formation when transfected in NIH3T3 cells. The semi-quantitative analysis of the foci density suggested that double mutants were more transforming than single mutants. This was consistent in three independent experiments but did not reach statistical significance (Fig. 1C) . The effect of p.R561C germline mutation was not detectable, by contrast to our previous findings (8) . However, in that report, we had used a longer incubation time to improve the sensitivity of the assay.
To further characterize the mutations, we performed a luciferase reporter assay driven by a serum-response element, as a readout of PDGFRB signaling. All the mutant forms identified in patients were constitutively activated in this assay, in contrast to the unstimulated wild-type receptor ( Fig. 2A) . We further analyzed PDGFRB signaling in NIH3T3 fibroblasts. We showed that the mutant receptors were constitutively phosphorylated on tyrosines, particularly on the lower band of the Western blot ( Fig. 2B) , which corresponds to immature receptors that have not undergone full glycosylation in the Golgi (21) . Mutants also activated multiple PDGFRB signaling pathways in the absence of ligand (Fig. 2C) . When comparing p.N666K with p.R561C, found together in patient C7, p.N666K had a much stronger impact on the transformation, intracellular signaling and receptor phosphorylation in NIH3T3 cells. The effect of p.R561C was only significant in our luciferase assay, as well as on phorphorylation of AKT and PLCc. These data suggest that the somatic p.N666K mutation confers a significant advantage over germline p.R561C, and are in line with our previous report (8) . Altogether, these data support the hypothesis that p.N666K represents a second hit that was required to fully activate PDGFRB in cells that were primed by p.R561C in patient C7.
PDGFRB mutants show variable levels of sensitivity to tyrosine kinase inhibitors
Our results pointed to tyrosine kinase inhibitors (TKIs) as a potential treatment for severe myofibromatosis. Indeed, several clinically-approved TKIs efficiently target PDGFRB, including imatinib, dasatinib and ponatinib. Imatinib is of particular interest because it is approved for the treatment of pediatric BCR-ABL-positive leukemia with limited side effects (22) . In a previous report, we had shown that the p.R561C and p.N666K mutants were sensitive to this drug whereas p.D850V was fully resistant (8) . In the present study, we first tested the sensitivity of the other mutants to imatinib in a luciferase reporter assay. Table 3 shows that imatinib inhibited the double mutants p.R561C/N666K and p.W566R/N666K, as well as the transmembrane domain p.I538_L539insR mutant. The mutant p.W566_V568delinsL was much more sensitive to this TKI, in line with our previous observations with juxtamembrane mutants (8) . Since p.D850V conferred resistance to imatinib, we tested the effect of dasatinib and ponatinib, which efficiently decreased the constitutive activity of this mutant (Fig. 3) . The p.D850V mutant was less sensitive to dasatinib than the wildtype receptor, but the efficiency of ponatinib was similar for both receptors (Fig. 3A) . These results were confirmed by analysing tyrosine phosphorylation levels of the receptors in transfected cells. Indeed, dasatinib and ponatinib did decrease phosphorylation of the p.D850V mutant, while imatinib had no impact (Fig. 3B) . Taken together, our results suggest that imatinib could be tested for the treatment of patients diagnosed with severe myofibromatosis and carrying sensitive PDGFRB mutations. Dasatinib or ponatinib may represent alternatives for resistant mutations.
Discussion
We identified PDGFRB mutations in six out of eight sporadic multifocal myofibromatosis patients. These findings considerably expand the number of patients who carry PDGFRB mutations, compared to the initial observations of PDGFRB alterations restricted to familial cases (4, 5) . The mutants were constitutively activated in functional assays, supporting their pathogenic role in the disease. All mutations were somatic, with one exception: in patient C7, a germline p.R561C substitution was associated with a p.N666K somatic change. A similar familial case had already been published by Cheung et al. (4) . We demonstrated that p.R561C only weakly activated the receptor in fibroblasts, while p.N666K was enough to fully activate PDGFRB, in agreement with our previously published observations (8). The p.R561C substitution was identified in most familial cases of myofibromatosis (4, 5) . An incomplete penetrance was suggested (23) , indicating that p.R561C is not sufficient to induce the disease. Germline mutations that fully activate PDGFRB may not be compatible with embryo development, as suggested by the early death of mouse embryos carrying a mutation corresponding to D850V (24) . Activating PDGFRB mutations also induce Kosaki overgrowth or Penttinen syndromes, which are not observed in p.R561C carriers. We propose a model for familial myofibromatosis in which the weak p.R561C substitution triggers the development of tumors only when combined with second hits that fully activate the receptor in the relevant cell type. The validation of this model will require a detailed analysis of multiple nodules in familial cases. We found multiple mutations in two other patients in our series. In C6, the same two mutations, p.W566R and p.N666K, were detected in every sample analyzed. Both substitutions are located on the same allele of PDGFRB and seem to be somatic, given the percentage of mutated reads. This suggests, once again, the occurrence of a double hit. In this case, sequencing multiple cDNA clones suggested that p.N666K arose first. The foci-forming assay also indicated that the double mutant was stronger than single mutants, although this was not confirmed in signaling assays. In patient C5, three different somatic mutations were found in three distinct lesions. We hypothesize that these alterations represent a second hit, following a first PDGFRB alteration that has not been identified. This observation is reminiscent of multifocal GIST cases, in which different KIT mutations were identified from multiple tumor nodules of the same patient (25) . Different somatic second-hit mutations leading to the same amino acid change in the receptor tyrosine kinase TIE2 (TEK) have also been identified in multiple lesions from a patient with inherited, multifocal cutaneomucosal venous malformation (26) .
The association of recurrent PDGFRB mutations with multifocal myofibromatosis will facilitate diagnosis and prognosis of this disease. During the preparation of the present manuscript, Agaimy and colleagues reported similar PDGFRB mutations in 6 out of 8 infantile and 11 out of 16 adult sporadic myofibromas, including p.N666K and juxtamembrane domain mutants, based on Sanger sequencing of exons 12 and 14 (27) . Mutations were not found in angioleiomyomas and myopericytomas. We confirm the presence of PDGFRB mutations in infantile myofibromas, and suggest a higher rate of mutants among multifocal cases, a distinction that was not present in Agaimy's data. We did not observe mutations in the three adults of our cohort, but this number is too limited to draw conclusions.
Our results show that PDGFRB sequencing should not be restricted to classical hotspots, such as exon 12. A targeted deep sequencing approach, like the one we used in the present study, may be more suited for covering a larger region of the gene and to detect low variant allele frequency. Of particular interest, we report for the first time a recurrent mutation in the PDGFRB transmembrane domain (p.I538_L539insR in exon 11). Although transmembrane domain mutants have been described in other RTKs, including ErbB2/Neu, PDGFRA, KIT and FGFR3 (14, 28) , the insertion of a positively charged amino acid residue in the hydrophobic transmembrane helix is very unusual.
In the recent WHO classification of tumors of soft tissue and bone, myofibromatosis is included in the chapter of pericytic (perivascular) tumors. Infantile myofibromatosis was once regarded as a form of haemangiopericytoma, because the tumor morphology was reminiscent of pericytic differentiation (29) . Since PDGFRB is highly expressed in that cell type, is considered as a selective pericyte biomarker and plays an essential role in pericyte development in mice (11) , our data support the hypothesis that sporadic myofibromatosis is a vascular disease, which originates from pericytes or their progenitors. cells stably expressing wild-type or mutant PDGFRB were starved for 8 h before cell lysis. As positive controls, cells expressing the empty vector or the wild-type receptor were stimulated with PDGF for 15 min before lysis. PDGFRB was isolated by immunoprecipitation and analyzed by western blot using an anti-phospho-tyrosine antibody. Membranes were re-probed with an anti-PDGFRB antibody. One representative blot out of three is shown. (C) Signaling downstream of the mutants. Cells were processed as in B and total cell lysates were analyzed by western blot (n¼3). Chronic STAT1 activation led to the increased STAT1 expression as described (40) .
The type of mutations and the pathophysiology of myofibromatosis are highly reminiscent of venous malformations induced by TIE2 mutations in endothelial cells. Similar compound mutations (comprising two somatic mutations on the same allele) were identified in TIE2 in sporadic venous malformations (30, 31) , and are significantly more frequent in rare, multifocal (as opposed to unifocal) forms of disease (26) . In addition, TIE2 mutations are also found in rare families as predisposing germline variants followed by a second somatic hit for lesion development.
Finally, we show that most mutants remain sensitive to imatinib, which is successfully used in other soft tissue tumors, such as dermatofibrosarcoma protuberans and GISTs (12) . Imatinib therapy was also reported in a few pediatric cases of myeloid neoplasms associated with eosinophilia and PDGFRB translocations (32) (33) (34) . The potential benefits of this treatment in myofibromatosis must be balanced with side effects, such as growth deceleration, which was described in children with chronic myeloid leukemia (22) . We also show that p.D850V conferred resistance to imatinib, similarly to the corresponding mutations PDGFRA-D842V and KIT-D816V in GISTs (14, 35) . Dasatinib and ponatinib overcame the D850V resistance in our cell culture assays; however, these drugs have not been approved for pediatric use yet. Our results underline the importance of a functional characterization of novel mutations.
In conclusion, we identified gain-of-function PDGFRB mutations in 6 out of 8 multicentric myofibromatosis and one solitary case. We suggest that myofibromatosis may be caused by germline or post-zygotic somatic mutations. Our data shed light on the pathogenesis of the disease, provide a genetic test as a diagnostic complement to pathological examination, and suggest a treatment for severe cases carrying PDGFRB mutants that are sensitive to TKI.
Materials and Methods
Ethics
This study was approved by the medical ethics review board of the University of Louvain.
Reagents and antibodies
PDGF-BB was purchased from PeproTech (Rocky Hill, NJ, USA). Imatinib and dasatinib were purchased from LC Laboratories (Woburn, MA, USA). Ponatinib was purchased from Selleck Chemicals (Munich, Germany). See supplementary material for detailed information regarding the antibodies used in the study.
Targeted next generation sequencing and data analysis
Genomic DNA was extracted from frozen cells (QIAamp DNA Blood Mini Kit, Qiagen, Hilden, Germany), frozen tissues (DNeasy Blood & Tissue Kit, Qiagen) or formalin-fixed paraffinembedded (FFPE) tissues (QIAamp DNA FFPE Tissue Kit, Qiagen), according to manufacturer's instructions. To sequence PDGFRB in these samples, we used different Ion AmpliSeq (IA) Custom DNA Panels (Life technologies, Grand Island, NY, USA) covering the PDGFRB coding sequence with at least 10 nucleotides of flanking introns (exon padding). Panel IA1 was used to sequence all exons of PDGFRA and PDGFRB from DNA extracted from frozen samples (100% coverage); IA2 was used for sequencing PDGFRB exons from DNA extracted from formalin-fixed paraffin-embedded tissue (95.35% coverage); and IA3 was used to confirm mutations by sequencing the whole gene, including the promoter, introns and UTRs (95.35% coverage). Panels are described in detail in the supplementary information. Each IA panel consists of two pools of multiple primers, which are used to prepare two different DNA libraries per sample from 15 ng of DNA. Ion AmpliSeq libraries were prepared and sequenced according to manufacturer's protocol as described (36) MCF7 cells were processed as described in Fig. 2A , except that they were treated with increasing doses of imatinib for 24 h. IC 50 was calculated as in Fig. 2A Luciferase experiments were performed as described (8, 28) . Briefly, MCF7 cells were seeded in 12-well plates (150,000 cells/ well) and transiently co-transfected with 3 different constructs: the wild-type (WT) or mutated receptors (0.5 mg), the b-galactosidase (0.5 mg) and the luciferase gene downstream of a serumresponse elements (SRE) promoter (0.5 mg) by using TurboFect TM Transfection Reagent (Thermo Scientific). Four hours after transfection, cells were washed and treated or not with PDGF-BB (20 ng/ml) and/or increasing doses of imatinib, dasatinib and ponatinib for 24 h. The luciferase activity was assessed by using a GloMax instrument (Promega, Leiden, The Netherlands) and divided by the b-galactosidase activity, as described (28) .
HEK-293T cells were seeded in 6-well plates (400,000 cells/ well) and transiently transfected with the wild-type receptor or the p.D850V mutant by using the calcium phosphate method (37) . Four hours after transfection, cells were washed. The next day, cells were treated with 500 nM imatinib, dasatinib or ponatinib for 4 h, or left untreated. PDGF-BB (25 ng/ml) was added in appropriated wells 15 min before cell lysis. Receptors were purified by immunoprecipitation with an anti-PDGFRB antibody as described (9) . Their phosphorylation level was analyzed by western blot with an anti-phospho-tyrosine antibody (PY99). Finally, membranes were re-probed with an anti-PDGFRB antibody to assess the receptor expression level.
Foci formation assay
NIH3T3 cells were transfected with 0.55 mg wild-type or mutated PDGFRB cloned in pcDNA3.1 with LipofectamineV R 2000 (Invitrogen, Life Technologies) according to manufacturer's instructions and were processed as described (38) .
Production of NIH3T3 stable cell lines expressing mutated PDGF receptors NIH3T3 cells were cultured in DMEM supplemented with 10% FCS. BOSC cells were cultured in Iscove's Modified Dulbecco's Medium (IMDM, Gibco, Life Technologies) supplemented with 10% FCS.
To produce retroviral particles, 2 million BOSC cells were cotransfected with a pCL-Eco plasmid and the wild-type or mutated receptor cloned in pBabe by using the calcium phosphate method as described (37) . The supernatant containing viruses was harvested 48 h after transfection, filtrated and added on 2 million NIH3T3 cells. Twenty-four hours after infection, cells expressing the receptors were selected with puromycin (1 mg/ml). Homogenous receptor expression was checked by flow cytometry as described (9, 39) .
For western blotting experiments, NIH3T3 were seeded in 6 well-plates (600,000 cells/well) and starved for 8 h in a medium without FCS before cell lysis. PDGF-BB (25 ng/ml) was added 15 min before cell lysis in cells expressing the empty vector and the wild-type receptor. PDGF receptors were isolated by immunoprecipitation and their phosphorylation and expression levels were analyzed as described above by western blot (9) . Total cell lysates were also analyzed by western blot with the antibodies listed in Supplementary Material, Table S2 . Membranes were first incubated with an antibody recognizing the phosphorylated form of the protein and then re-probed with an antibody targeting the corresponding protein.
Statistics
All experiments were performed at least three times, unless otherwise stated. The average of different experiments is shown with standard error of the mean (S.E.M.). Normal distribution was tested. Statistical analyses were performed using Student's t-test (*P < 0.05; **P < 0.01; ***P < 0.001).
Supplementary Material
Supplementary Material is available at HMG online.
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